The Trump administration has authorized a 100% tariff on certain imported pharmaceuticals, aiming to pressure drug manufacturers to increase production in the United States. While the tariffs primarily target patented drugs from countries without favorable pricing agreements, major companies like Pfizer and Eli Lilly have negotiated exemptions, limiting the overall impact. Analysts estimate that only about $12 billion of the $274 billion in total US pharmaceutical imports will be affected, representing less than 5% of the total. The tariffs will take effect in 120 days for larger companies and 180 days for smaller manufacturers. Critics, including industry leaders, warn that these tariffs could raise costs for consumers and disrupt supply chains, potentially jeopardizing billions in investments in the US pharmaceutical sector. The move follows Trump's long-standing criticism of foreign medicine production as a national security threat and is part of a broader protectionist trade agenda.